Tags : Marker Therapeutics

Terumo BCT and Marker Therapeutics Receive the US FDA’s Emergency

Shots: The US FDA has granted EUA to Terumo BCT’s Spectra Optia Apheresis System combined with Marker Therapeutics’ D2000 Adsorption Cartridge to treat patients aged ≥18yrs. with confirmed COVID-19 and are admitted to the ICU with confirmed or imminent respiratory failure to reduce pro-inflammatory cytokine levels The device works by reducing the number of cytokines […]Read More